{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=6", "query": { "intervention": "ABI-007(Abraxane)", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 2447, "total_pages": 245, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABI-007%28Abraxane%29&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T17:18:43.274Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07552181", "title": "Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "TNBC - Triple-Negative Breast Cancer", "TNBC", "Early Stage Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Live biotherapeutic product: MO-03 1 capsule PO BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yuan Yuan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-09", "completion_date": "2035-09", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 3, "location_summary": "Beverly Hills, California • Tarzana, California • Torrance, California", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07552181" }, { "nct_id": "NCT00828009", "title": "BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "Tecemotide", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2011-01-17", "completion_date": "2019-05-22", "has_results": true, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 88, "location_summary": "Palo Alto, California • Stanford, California • Macon, Georgia + 61 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Macon", "state": "Georgia" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00828009" }, { "nct_id": "NCT00005819", "title": "Combination Chemotherapy in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fenretinide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2000-04", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005819" }, { "nct_id": "NCT01507428", "title": "Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "18F-Fluoromisonidazole", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Fludeoxyglucose F-18", "type": "DRUG" }, { "name": "Image-Guided Adaptive Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2012-02-22", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 29, "location_summary": "Palo Alto, California • Augusta, Georgia • Chicago, Illinois + 23 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01507428" }, { "nct_id": "NCT06726265", "title": "Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "eftilagimod alfa", "type": "BIOLOGICAL" }, { "name": "carboplatin plus paclitaxel", "type": "DRUG" }, { "name": "cisplatin or carboplatin + pemetrexed", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Immutep S.A.S.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 756, "start_date": "2025-03-21", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 3, "location_summary": "Louisville, Kentucky • Albuquerque, New Mexico • Austin, Texas", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06726265" }, { "nct_id": "NCT02395744", "title": "The COPPER-B Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Diseases", "Peripheral Vascular Disease", "Arterial Occlusive Diseases", "Peripheral Arterial Disease", "Critical Limb Ischemia" ], "interventions": [ { "name": "Paclitaxel administration using the OPC", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Horizons International Peripheral Group", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2015-03-11", "completion_date": "2017-02-23", "has_results": false, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 4, "location_summary": "Fairhope, Alabama • Houma, Louisiana • Dearborn, Michigan + 1 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Houma", "state": "Louisiana" }, { "city": "Dearborn", "state": "Michigan" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02395744" }, { "nct_id": "NCT00392704", "title": "Treatment of Head & Neck Cancer With Chemotherapy and Radiation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2006-12", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-02-22", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 7, "location_summary": "Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392704" }, { "nct_id": "NCT02297230", "title": "Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Radiation Therapy (RT)", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 44, "start_date": "2002-06", "completion_date": "2014-12-02", "has_results": true, "last_update_posted_date": "2018-10-15", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02297230" }, { "nct_id": "NCT07720167", "title": "Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Carboplatin + Pemetrexed/Paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 38, "start_date": "2026-11-01", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07720167" }, { "nct_id": "NCT03587311", "title": "Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Anetumab Ravtansine", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2018-10-12", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-13T17:18:43.274Z", "location_count": 22, "location_summary": "Orange, California • Aurora, Colorado • Coral Gables, Florida + 19 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587311" } ] }